WO1996031217A1 - Inhibition de la replication des retrovirus - Google Patents

Inhibition de la replication des retrovirus Download PDF

Info

Publication number
WO1996031217A1
WO1996031217A1 PCT/US1996/004084 US9604084W WO9631217A1 WO 1996031217 A1 WO1996031217 A1 WO 1996031217A1 US 9604084 W US9604084 W US 9604084W WO 9631217 A1 WO9631217 A1 WO 9631217A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
nitroso
nitric oxide
retrovirus
animal
Prior art date
Application number
PCT/US1996/004084
Other languages
English (en)
Other versions
WO1996031217A9 (fr
Inventor
Jonathan S. Stamler
Robert W. Finberg
Joan B. Mannick
Original Assignee
Duke University
Dana-Farber Cancer Institute
Brigham And Women's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, Dana-Farber Cancer Institute, Brigham And Women's Hospital filed Critical Duke University
Priority to AU55271/96A priority Critical patent/AU5527196A/en
Publication of WO1996031217A1 publication Critical patent/WO1996031217A1/fr
Publication of WO1996031217A9 publication Critical patent/WO1996031217A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0094—Gaseous substances

Definitions

  • This invention relates to the field of inhibiting retroviral replication in vitro and in vivo and to the treatment in humans and other animals of active and latent retroviral infections.
  • the invention is based on the discovery by the inventors that nitric oxide and adducts thereof which are nitric oxide donors inhibit retroviral replication and provides a method for inhibiting the replication of a retrovirus by exposing the retrovirus to nitric oxide or a nitric oxide-releasing, donating or transferring substance.
  • the present invention provides a method for inhibiting retroviral replication in a retrovirally infected cell or tissue culture in vitro which comprises contacting said retrovirally infected cell or tissue culture with an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected cell or tissue culture.
  • Another aspect of the invention provides a method for inhibiting retroviral replication in a retrovirally infected animal which comprises administering to said retrovirally infected animal an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected animal.
  • Another aspect of the invention provides a method for inhibiting retroviral replication in a retrovirally infected individual which comprises administering to said retrovirally infected individual an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected individual.
  • Another aspect of the invention provides a method for inhibiting the reactivation of latent retrovirus in a retrovirally infected cell or tissue culture which comprises contacting said retrovirally infected cell or tissue culture with a retrovirus reactivation inhibiting amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance which may be used prophylactically to prevent reactivation of latent retrovirus. This is very useful in mitigating the dangers of sample handling for research, laboratory and hospital personnel.
  • Another aspect of the invention provides a method for inhibiting the reactivation of a latent retrovirus infection in an animal in need thereof which comprises administering to said animal in need thereof an amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance sufficient to inhibit reactivation of latent retrovirus in said animal.
  • Another aspect of the invention provides a method for inhibiting the reactivation of a latent retrovirus infection in an individual in need thereof which comprises administering to an individual in need thereof an amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance sufficient to inhibit reactivation of latent retrovirus in said individual.
  • This is very useful, for example, in an lmmunocompromised host in which reactivation at an inopportune time (e.g. when defenses are low due to chemotherapy) would cause significant morbidity.
  • the invention is further based on the discovery by the inventors that nitric oxide synthase inhibitors and nitric oxide scavengers activate latent retrovirus. This is the first demonstration of a mechanism for eradicating the latent state, i.e.. once activated, the retrovirus can then be eliminated with antiviral therapy. Thus, this aspect of the present invention is directed to the use of nitric oxide synthase inhibitors as a means to eradicate latent virus.
  • another aspect of the invention provides a method for preventing or reversing retroviral latency in a retrovirally infected cell or tissue culture in vitro which comprises contacting a retrovirally infected cell or tissue culture in vitro with a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the latent retrovirus in the retrovirally infected cell or tissue culture replication-competent.
  • a nitric oxide synthase inhibitor or nitric oxide scavenger such as hemoglobin
  • compositions for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecung said animal rep cauon-competent and (ii) a retrovirus replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
  • Another aspect of the invention provides a method for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises administering thereto (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said animal replication-competent and (ii) a retroviral replication inhibitory amount of an antiviral agent.
  • a nitric oxide synthase inhibitor or nitric oxide scavenger such as hemoglobin
  • compositions for the treatment of a latent retrovirus infection in an individual infected with a latent retrovirus infection which comprises (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said individual replication-competent and (ii) a retrovirus replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
  • Another aspect of the invention provides a method for the treatment of a latent retrovirus infection in an individual infected with a latent retrovirus infection which comprises administering thereto (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said individual replication-competent and (ii) a retroviral replication inhibitory amount of an antiviral agent.
  • a nitric oxide synthase inhibitor or nitric oxide scavenger such as hemoglobin
  • Retroviruses whose growth may be inhibited in accordance with the method of the present invention include, but are not limited to, human immunodeficiency virus (HIV), human T-cell leukemia virus-1 (HTLV-1) and simian immunodeficiency virus (SIV).
  • HIV human immunodeficiency virus
  • HTLV-1 human T-cell leukemia virus-1
  • SIV simian immunodeficiency virus
  • the administration can be topical, by inhalation, oral, or parenteral.
  • the treated infection can be localized or systemic.
  • Figures 1A-1D show that NO generating compounds inhibit HIV-1 replication in human peripheral blood mononuclear cells and in the chronically infected human T cell line H9:
  • Figure 1A shows results when human peripheral blood mononuclear cells (PBMCs) stimulated with PHA and IL-2 were infected with HIV-1. and then grown in the presence or absence of the NO generating compound S-nitroso-N- acetyl-penicillamine (SNAP), or the parent compound N-acetyl-penicillamine (NAP);
  • Figure IB shows the results when the same experiment as shown in Figure 1A was performed using the NO-generating compound S-nitroso-N-acetyl- cysteine (SNAC) or the parent compound N-acetyl cysteine (NAC);
  • Figure IC shows the results when H9 cells were grown in the presence or absence of the NO generating compound SNAP.
  • Figure ID shows the results when the same experiment as shown in Figure IC was performed using the NO generating compound S-nitroso-penicillamine (SNP) or the control compound penicillamine (P).
  • SNP S-nitroso-penicillamine
  • P control compound penicillamine
  • Figures 2A-2B show the effect of NO on PBMC proliferation:
  • Figure 2A shows the results when human peripheral blood mononuclear cells are stimulated with PHA and IL-2 were grown in the presence or absence of the NO-generating compound SNAP or the parent compound NAP; and Figure 2B shows the results when the same experiment as shown in Figure 2A was performed using the NO-generating compound S-nitroso-N-acetyl cysteine (SNAC) or the control compound N-acetyl cysteine (NAC).
  • SNAC S-nitroso-N-acetyl cysteine
  • NAC N-acetyl cysteine
  • Figures 3A-3B show that iNOS is expressed constitutively in U-937 cells
  • Figure 3A shows cDNA that was made from whole cell RNA from U- 937 or from the control B cell line B-958 which is known to express iNOS;
  • Figure 3B shows a western blot that was performed on whole cell lysates made from 0.5xl0 6 U-937 cells (U-937), the human B cell line BL-30. and rat macrophages stimulated with LPS (Rat).
  • Figures 4A-4B show that endogenously produced NO inhibits HIV replication and HIV reactivation:
  • FIG. 4A shows the results when U-937 cells were infected with HIV-1 and then grown in the presence or absence of the NOS inhibitor L-NMA:
  • Figure 4B shows the results when the latently infected Ul cell line was grown in the presence or absence of L-NMA and TNF ⁇ .
  • Figure 5 shows the effect of cGMP on HIV replication. Peripheral blood mononuclear cells were infected with HIV-1 and then grown in the presence or absence of SNAP. NAP or the cGMP analog 8-bromo-cGMP.
  • nitric oxide and compounds that release nitric oxide or otherwise directly or indirectly deliver or transfer nitric oxide to a site of its activity, such as on a cell membrane, in vivo.
  • nitric oxide encompasses uncharged nitric oxide(NO») and charged nitric oxide species, particularly including nitrosonium ion(NO 'f ) and nitroxyl ion(NO ).
  • the reactive form of nitric oxide can be provided by gaseous nitric oxide.
  • nitric oxide releasing, delivering or transferring compounds having the structure X-NO wherein X is a nitric oxide releasing, delivering or transferring moiety, include any and all such compounds which provide nitric oxide to its intended site of action in a form active for their intended purpose.
  • NO adducts encompasses any of such nitric oxide releasing, delivering or transferring compounds, including, for example, S-nitrosothiols, S- nitroso amino acids, S-nitroso-polypeptides, and nitrosoamines. It is contemplated that any or all of these "NO adducts can be mono- or poly- nirosylated at a variety of naturally susceptible or artificially provided binding sites for nitric oxide.
  • S-nitrosothiols which are compounds that include at least one -S-NO group.
  • Such compounds include S-nitroso- polypeptides (the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof): S- nitrosylated amino acids(including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); S-nitrosated sugars, S- nitrosated-modified and unmodified oligonucleotides (preferably of at least 5.
  • S-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon: S-nitroso hydrocarbons having one or more substituent groups in addition to the S-nitroso group; and heterocyclic compounds.
  • S-nitrosothiols and the methods for preparing them are described in U.S. Patent Application No. 07/943.834, filed September 14. 1992, Oae et al.. Org. Prep. Proc. Int., 15.(3): 165-198 (1983); Loscalzo et al.. J. Pharmacol. Exp. Ther.. 242(3):726729 (1989) and Kowaluk et al.. J. Pharmacol. Exp. Ther., 2-5£: 1256- 1264 (1990), all of which are incorporated in their entirety by reference.
  • One particularly preferred embodiment of this aspect relates to S-nitroso amino acids where the nitroso group is linked to a sulfur group of a sulfur-containing amino acid or derivative thereof.
  • such compounds include the following: S-nitroso-N-acetylcysteine, S-nitroso-captopril, S-nitroso-homocysteine. S-nitroso-cysteine and S-nitroso-glutathione.
  • Suitable S-nitrosylated proteins include thiol-containing proteins(where the NO group is attached to one or more sulfur group on an amino acid or amino acid derivative thereof) from various functional classes including enzymes, such as tissue- type plasminogen activator(TPA) and cathepsin B; transport proteins, such as lipoproteins, heme proteins such as hemoglobin and serum albumin: and biologically protective proteins, such as the immunoglobulins and the cytokines.
  • TPA tissue- type plasminogen activator
  • cathepsin B transport proteins, such as lipoproteins, heme proteins such as hemoglobin and serum albumin: and biologically protective proteins, such as the immunoglobulins and the cytokines.
  • nitrosylated proteins are described in PCT Publ. Applic. No. WO 93/09806, published May 27, 1993. Examples include polynitrosylated albumin where multiple thiol or other nucleophilic centers in the protein are modified.
  • S-nitrosothiols include those having the structures:
  • aryl includes benzyl, naphthyl. and anthracenyl groups.
  • S-nitroso-ACE inhibitors S-nitroso-angiotensin converting enzyme inhibitors
  • S-nitroso-ACE inhibitors S-nitroso-angiotensin converting enzyme inhibitors
  • R is hydroxy, NH 2 , NHR 4 , NR 4 R ⁇ or C,-C 7 alkoxy, wherein R 4 and R 5 are C,-C 4 alkyl, or phenyl, or C,-C 4 alkyl substituted by phenyl;
  • R 1 is hydrogen, C C 7 alkyl, or C,-C 7 alkyl substituted by phenyl, amino, guanidino, NHR 6 , NR 6 R 7 , wherein R 6 and R 7 are methyl or C r C 4 alkanoyl;
  • R 2 is hydrogen, hydroxy, C,-C 4 alkoxy, phenoxy, or C,-C 7 alkyl
  • R 3 is hydrogen, C r C 4 or C,-C 7 alkyl substituted by phenyl; m is 1 to 3; and n is 0 to 2.
  • S-nitroso-ACE inhibitors include N-acetyl-S-nitroso-D-- cysteinyl-L-proline, N-acetyl-S-nitroso-D,L-cysteinyl-L-proline, l-[4-amino-2-(S- nitroso)mercaptomethyl butanoyl]-L-proline, l-[2-hexanoyl]-L-proline.
  • S-nitroso-ACE inhibitors include those having structures
  • A is ON-S-CH,-CH-C;
  • R is selected from hydrogen, lower (C,-C 4 ) alkyl, benzyl, benzhydryl, and salt forming ion:
  • R, and R are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy. halo substituted lower alkyl, nitro. and S0 2 NH 2 ; 0 0 0
  • Z is -C- or -S-
  • R 3 is hydrogen, lower alkyl, halo substituted lower alkyl, phenyl, benzyl, phenethyi, or cycloalkyl;
  • R 4 is hydrogen, lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, -(CH 2 ) q -N (lower alkyl), or -(CH 2 ) q -NH, and q is one, two, three or four.
  • the S-nitroso-ACE inhibitors can be prepared by various methods of synthesis.
  • Acids which may be used for this purpose include aqueous sulfuric. acetic and hydrochloric acids.
  • Thiol precursors are prepared as described in the following: U.S. Pat. Nos. 4.046,889 ( 1977); 4.052,51 1 : 4,053,651 ; 4, 1 13,751 , 4.154,840, 4129,571 ( 1978), and 4.
  • Such compounds include O-nitroso-polypeptides(the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); O-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); O-nitrosated sugars; O-nitrosated-modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200. nucleotides); and an O-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched.
  • NO adducts saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon: O-nitroso hydrocarbons having one or more substituent groups in addition to the O-nitroso group; and heterocyciic compounds.
  • Another group of such NO adducts is the nitrites which have an -O-NO group wherein R is a protein, polypeptide. amino acid, branched or unbranched and saturated or unsaturated alkyl. aryl or a heterocyclic.
  • R is a protein, polypeptide. amino acid, branched or unbranched and saturated or unsaturated alkyl. aryl or a heterocyclic.
  • a preferred example is tJne nitosylated form of isosorbide.
  • Compounds in this group form S-nitrosothiol intermediates in vivo in the recipient human or other animal to be treated and can therefore include any structurally analogous precursor R-O-NO of the S-rutrosothio
  • N-nitrosoammes are compounds that include at least one -N-NO group.
  • Such compounds include N- mtroso-polypeptides (the term “polypepnde” includes proteins and also polyamino acids that do not possess an ascertained biological function, and denvauves thereof); N-nitrosylated ammo acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures); N-rutrosated sugars; N-mtrosated-modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and an N-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; N-nitroso hydrocarbons having one or more substituent groups in addition to the N-mtroso group; and heterocyclic compounds.
  • C-rutroso compounds that include at least one -C-NO group.
  • Such compounds include C-nitroso-polypepUdes (the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and denvatives thereof); C-nitrosylated amino acids (including natural and synthetic ammo acids and their stereoisomers and racemic mixtures); C-nitrosated sugars; C-rutrosated-modified and unmodified oligonucleotides (preferably of at least 5.
  • hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic 96/31217 PCI7US96/04084
  • hydrocarbon C-nitroso hydrocarbons having one or more substituent groups in addition to the C-nitroso group; and heterocyclic compounds.
  • polypeptides include proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof: amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); sugars: modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200. nucleotides); and a hydrocarbon where the hydrocarbon can be a branched or unbranched. and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or more substituent groups; and heterocyclic compounds.
  • a preferred example is nitroglycerin.
  • R includes polypeptides(the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); sugars; modified and unmodified oligonucleotides (preferably of at least 5.
  • A is S, O, or N
  • n and x are each integers independently selected from 1. 2 and 3.
  • M is a metal, preferably a transition metal.
  • Prefened metals include iron, copper, manganese, cobalt, selenium and luthidium. Also contemplated are N-rutrosylated metal centers such as nitroprusside.
  • R includes polypeptides (the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); ammo ac ⁇ ds( including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); sugars; modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and a hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or more substituent groups; and heterocyclic compounds.
  • R is preferably a nucleophilic (basic) moiety.
  • M + is a metal cation, such as, for example, a Group 1 metal cation
  • thionitrates which have the structure R-(S) x -NO wherein x is an integer of at least 2.
  • R is as described above for the S- nitrosothiols.
  • dithiols wherein x is 2.
  • Particularly preferred are those compounds where R is a polypeptide or hydrocarbon and a par or pairs of thiols are sufficiently structurally proximate, i.e. vicinal, that the pair of thiols will be reduced to a disulfide.
  • Those compounds which form disulfide species release nitroxyl ⁇ on(NO ) and uncharged nitric ox ⁇ de(NO»).
  • Those compounds where the thiol groups are not sufficiently close to form disulfide bridges generally only provide nitric oxide as the NO form but not as the uncharged NO* form.
  • Agents which stimulate endogenous NO synthesis are also suitable for use in accordance with the invention.
  • Viruses whose replication may be inhibited or prevented by the compounds described hereinabove include retroviruses such as human immunodeficiency virus (HIV), human T-cell leukemia v ⁇ rus- 1 (HTLV-1), and simian immunodeficiency virus (SIV).
  • retroviruses such as human immunodeficiency virus (HIV), human T-cell leukemia v ⁇ rus- 1 (HTLV-1), and simian immunodeficiency virus (SIV).
  • these compounds can be employed in various therapeutic treatments, including: 1 ) the incorporation of NO donors into creams, salves or lotions for the treatment of topical infections: 2) the use of inhaled nitric oxide and other NO donors for the treatment of lung infections: 3) the use of topical drops and creams for the treatment of mucocutaneous membrane infections, such as infections of the eye, mouth and genitourinary tract; and 4) oral or parenteral administration for systemic or localized infections.
  • the nitric oxide When administered in vivo, the nitric oxide may be administered in combination with pharmaceutical carriers and in dosages described herein.
  • Certain viruses can both replicate (lytic phase) and also incorporate themselves into the genome (latency).
  • the virus When latent, the virus may serve as a protooncogene. thereby promoting cancer; and it is also resistant to antiviral therapy. Thus, the establishment of latency prevents elimination of virus with antiviral therapy.
  • Another aspect of the invention is based on the discovery that nitric oxide synthase inhibitors activate latent retrovirus. This is the first demonstration of a mechanism for eradicating the latent state, i.e., once activated, the retrovirus can then be eliminated with antiviral therapy. Thus, this aspect of the present invention is directed to the use of nitric oxide synthase inhibitors as a means to eradicate latent virus.
  • the invention provides a method for preventing or reversing retroviral latency in a cell, tissue or animal infected therewith which comprises administering thereto a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent.
  • this aspect of the invention provides a method for the treatment of a latent retrovirus infection in a cell, tissue or animal so-infected, which comp ⁇ ses administering thereto (i) a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent.
  • this aspect of the invention provides a composition for the treatment of a latent retrovirus infection in a cell, tissue or animal so- infected, which comprises (i) a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
  • Suitable nitric oxide synthase inhibitors include arginine derivatives such as N G -monomethyl-L-arginine (NMA), nitro-arginine, diphenylene iodonium and related iodonium derivatives, N-nitro-L-arginine methyl ester, N-methyl-L-arginine, N- amino-L-arginine, ornithine, N-imino-ethyl-L-ornithine and ornithine derivatives, N- nitro-L-arginine, methylene blue, heme binders, trifluoropiperazine, and calcinarin and other calmodulin binders, such as methotrexate.
  • NMA N G -monomethyl-L-arginine
  • NMA nitro-arginine
  • diphenylene iodonium and related iodonium derivatives N-nitro-L-arginine methyl ester
  • antiviral agent refers to any agent that inhibits, prevents, or destroys the growth or replication of a retrovirus.
  • the antiviral agent can be a purine nucleoside analog such as acyclovir or didanosine.
  • the antiviral agent can be a pyrimidine nucleoside analog such as zidovudine, trifluridine and zalcitabine.
  • the antiviral agent can also be a chelating agent such as foscarnet sodium.
  • the antiviral agent can be an intercalating agent.
  • the antiviral agent can be an interferon, preferably an ⁇ -interferon, a ⁇ -interferon or a 7- interferon.
  • Treatment of localized topical infection with the nitnc oxide or rutnc oxide releasing agent compnses contacting the surface so as to cause the surface to be coated with the nitnc oxide or nitnc oxide releasing agent.
  • Coating may be accomplished using standard methods well known to those of ordinary skill in the art. For example, coating a surface with nitnc oxide adducts can be achieved by bathing the surface in a solution containing the nitnc oxide adduct.
  • synthetic mtnc oxide adducts may be coated onto an artificial surface such as a bandage or covenng by a vanety of chemical techmques which are well known in the art.
  • Modes of administration include but are not limited to topical, transdermal, intramuscular, intrapentoneal, intravenous, vaginal, subcutaneous, intranasal. topical and oral routes.
  • the compounds may be administered by any convenient route, for example by infusion or bolus injection by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa. rectal and intestinal mucosa. etc.) and may be administered together with other biologically active agents.
  • Pnncipal approaches to therapeutic uses of the invention include topical administration to treat skin infections; topical administration to treat genital and oral lesions; topical administration to treat eye infections; topical or inhalation administration of NO/or SNAC to treat respiratory infections; and particularly intravenous administration to treat systemic infection.
  • the compounds of this invention can be employed in combination with conventional excipients, 1. e., pharmaceutically acceptable organic or inorganic earner substances suitable for parenteral application which do not deletenously react with the active compounds.
  • suitable pharmaceutically acceptable earners include, but are not limited to, water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycendes and diglycendes, petroethral fatty acid esters, hydroxymethylcellulose. polyvinylpyrrolidone, etc.
  • the pharmaceutical preparations can be sten zed and if desired, mixed with auxiliary agents, e.g.
  • lubncants for influencing osmotic pressure, buffers, colonngs, flavonng and/or aromatic substances and the like which do not deletenously react with the active compounds.
  • suitable vehicles consist of solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants.
  • Aqueous suspensions may contain substances which increase the viscosity of the suspension and include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the suspension may also contain stabilizers.
  • the composition can also contain minor amounts of wetting or emulsifying agents, or pH buffe ⁇ ng agents.
  • the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • the composition can be formulated as a suppository, with traditional binders and earners such as tnglyce ⁇ des.
  • Oral formulations can include standard earners such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate. sodium saccha ⁇ ne, cellulose, magnesium carbonate, etc.
  • Vanous delivery systems are known and can be used to admimster a therapeutic compound or composition of the invention, e.g. , encapsulation in liposomes, microparticies, microcapsules and the like.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in stenle lsotoruc aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic to ameliorate any pain at the sue of the injection.
  • the ingredients are supplied either separately or mixed together in umt dosage form, for example, as a drylyophihzed powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to admimstration.
  • the therapeutics of the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, sulfuric, acetic, oxalic, tartaric acids, etc. , and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanoi. histidine. procaine, etc.
  • terapéuticaally effective amount refers to the amount of the nitric oxide adduct which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges for effective amounts of each nitric oxide adduct is within the skill of the art. Generally, the dosage required to provide an effective amount of the composition, and which can be adjusted by one of ordinary skill in the art will vary, depending on the age, health, physical condition, sex, weight, extent of disease of the recipient, frequency of treatment and the nature and scope of the disorder.
  • the amount of the therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. The precise dose to be employed in the formulation will also depend on the route of admimstration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.
  • suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight.
  • Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight.
  • Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems and are in the same ranges or less than as described for the commercially available compounds in the Physician's Desk Reference. Medical Economics Company, Inc., Oradell, N.J. 1990.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • Peripheral blood mononuclear cells isolated from HIV-1 negative adult donors were stimulated for 48 hours with 10 ⁇ g/ml of PHA.
  • the cells were then infected with HIV- 1 strain MN at an MO1 of 0.1 for 1-2 hours at 37°C, washed three times and resuspended at 500,000 cells/ml in complete medium (RPMI 1640 10% fetal bovine serum) supplemented with 10 units/ml of 1L-10 with or without various concentrations of SNAP, NAP, SNAC or NAC.
  • the cells were then plated in 24 well plates with 2 ml of cells per well. After 4 days, the cells were split and refed with the same media in which they were originally resuspended. After 5-8 days in culture, cell supernatants were collected, and p24 antigen levels determined using the HIV- 1 p24 Core Profile assay (NEN) as per the manufacturer's instructions.
  • H9 cells were pelleted and infected with HIV-1 strain MN at an MOI of 0.1 for 1-2 hours at 37° C. washed three times, resuspended at a concentration of 100,000 cells/ml in complete medium supplemented with or without SNAP, NAP, SNOP or penicillamine, and plated in 24 well plates with 2 ml of cells per well. After 3 days, p24 antigen levels were measured in the H9 cell supernatants using the method described above.
  • U937 cells were pelleted and infected with HIV-1 strain MN at an MOI of 0.2 for 1-2 hours at 37°C, washed three times and then resuspended at 100,000 cells/ml in RPMI 1640 containing 10% FBS and 0.1 mM arginine with or without L- NMA. The cells were then plated in 24 well plates containing 2 ml of cells per well. Twice a week the cells were split and refed with the same media in which they were originally resuspended. After 8-14 days, p24 antigen levels were measured in the cell supernatants using the method described above.
  • Ul cells were resuspended at a concentration of 100.000 cells per ml in RPMI 1640 (GIBCO) containing 10% FBS and 0.1 mM arginine with or without TNF- ⁇ or L-NMA. The cells were then plated in 24 well plates containing 2 ml of cells per well. After 48-72 hours in culture, p24 antigen levels were measured in the cell supernatants using the method described above.
  • the effect of NO generating compounds on HIV- 1 replication was determined by growing human peripheral blood mononuclear cells (PBMCs) infected with HIV-1 (MN strain) in the presence or absence of NO-generating compounds or control parent compounds which do not generate NO. The extent of HIV-1 replication was determined 5 to 8 days after infection by measuring p24 antigen levels in the cell supernatants.
  • Figures 1A-1D shew that NO generating compounds inhibit HIV-1 replication in human peripheral blood mononuclear cells and in the chronically infected human T cell line H9.
  • Figure 1A shows results when human peripheral blood mononuclear cells (PBMCs) stimulated with PHA and IL-2 were infected with HIV-1 , and then grown in the presence or absence of the NO generating compound S-nitroso-N-acetyl- penicillamine (SNAP), or the parent compound N-acetyl-penicillamine (NAP).
  • SNAP S-nitroso-N-acetyl- penicillamine
  • NAP N-acetyl-penicillamine
  • the data are expressed as the percent of control p24 levels. Since SNAP and NAP were diluted in ETOH, the effect of 0.2 % ETOH (the concentration present in 200 uM SNAP and NAP cultures) was determined. The results represent the mean of 9 separate experiments ⁇ SEM for 100. 200. and 300 uM SNAP or NAP. and the mean of 2 separate experiments for 10, 50, 150 and 250 uM SNAP or NAP concentrations.
  • Figure IB shows the results when the same experiment as shown in Figure 1 A was performed using the NO-generating compound S-nitroso-N-acetyl-cysteine (SNAC) or the parent compound N-acetyl cysteine (NAC). Similar effects were seen with the NO-generating compound S-nitroso-N-acetyl-cysteine (SNAC) and the control parent compound N-acetyl-cysteine (NAC). The data are expressed as the mean of duplicate cultures.
  • Figure IC shows the results when H9 cells were grown in the presence or absence of the NO generating compound SNAP; and After three days in the culture. p24 levels in the cell supernatants were measured by ELISA. Again, the NO donor SNAP inhibited HIV replication in a dose dependent fashion. The data are expressed as the mean of duplicate cultures and are repesentative of one of three expenments.
  • Figure ID shows the results when the same expenment as shown in Figure IC was performed using the NO generating compound S-nitroso-penicillamine (SNP) or the control compound penicillamine (P). Similar results were seen with the NO donor S-nitroso-penicillamine (SNP) but not with the parent compound penicillamine (P). The data are expressed as the mean of duplicate cultures.
  • Figures 2A-2B show the effect of NO on PBMC proliferation.
  • Figure 2A shows the results when human pe ⁇ pheral blood mononuclear cells stimulated with PHA and IL-2 were grown in the presence or absence of the NO- generating compound SNAP or the parent compound NAP.
  • the effects of SNAP or NAP on PBMC proliferation were analyzed by tntiated thymidine uptake. Higher concentrations of SNAP (i.e. 200 uM-500 uM) inhibited PBMC proliferation, however, 50-150 uM SNAP did not inhibit PBMC proliferation and yet inhibited p24 antigen production (Figure 1A). After 6 days in culture, [ 3 H]-thym ⁇ d ⁇ ne uptake was measured.
  • SNAP and NAP were diluted in ETOH and therefore, as a control, the effect of ETOH on PBMC proliferation was measured.
  • concentrations of ETOH present in 100. 200. 300. and 400 uM SNAP or NAP were 0.1 %. 0.2%, 0.3 %. and 0.4 % ETOH. respectively.
  • Figure 2B shows the results when the same experiment as shown in Figure 2A was performed using the NO-generating compound S-nitroso-N-acetyl cysteine (SNAC) or the control compound N-acetyl cysteine (NAC). After 6 days in culture the number of viable cells was determined by trypan blue staining. Concentrations of SNAC which inhibited HIV replication (Figure IB) had no effect on PBMC proliferation. Thus NO appears to have an inhibitory effect on HIV replication which is independent of its anti-proliferative effect.
  • SNAC S-nitroso-N-acetyl cysteine
  • NAC N-acetyl cysteine
  • NO synthase (NOS) activity is difficult to demonstrate in human mononuclear cells, presumably because they express very low levels of NOS.
  • inducible NOS(iNOS) expression and activity was evident in the U-937 human promonocytic cell line.
  • Figures 3A-3B show that iNOS is expressed constitutively in U-937 cells.
  • Figure 3A shows cDNA that was made from whole cell RNA from U-937 or from the control B cell line B-958 which is known to express iNOS. Samples to which reverse transcriptase was ( + RT) or was not (-RT) added are indicated. Equal amounts of each sample were PCR amplified using primers specific for human iNOS. The markers on the left indicate the base pair size of OX DNA fragments generated from an Hae III digest. iNOS RNA expression was detected in U-937 cells by RT- PCR using human iNOS-specific primers. This RT-PCR product was sequenced and found to be identical to the human hepatic iNOS cDNA sequence.
  • Figure 3B shows a western blot that was performed on whole cell lysates made from 0.5xl0 6 U-937 cells (U-937).
  • INOS expression was detected using an affinity purified rabbit antiserum was raised against the C-terminal 20 amino acids of the rat isoform and recognizes both human and rat iNOS (Kobzik et al. 1993).
  • the rat isoform which shares 80 % homology with the human isoform. runs slightly below the human isoform on polyacrylamide gels.
  • NO production by U- 937 cells was detected by a photolysis/chemilumincesence assay.
  • Figure 4A shows the results when U-937 cells were infected with HIV-1 and then grown in the presence or absence of the NOS inhibitor L-NMA; and After 8-10 days in culture, p24 levels in the cell supernatants were determined by ELISA. Inhibition of endogenous NO synthesis by L-NMA caused a small but statistically significant increase in p24 antigen levels, with maximal effects seen between 100-250 uM L-NMA. The L-NMA-induced increase in p24 levels was abrogated by the addition of excess L-arginine, the NOS substrate. Thus, both endogenously synthesized NO and exogenous NO appear to inhibit HIV replication. The data represent the mean of 5 duplicate cultures and are representative of three separate experiments.
  • Figure 4B shows the results when the latently infected Ul cell line was grown in the presence or absence of L-NMA and TNF ⁇ . and after 2-3 days in culture p24 antigen levels were measured in the cell supernatants by ELISA.
  • L-NMA caused a dose dependent increase in p24 antigen levels with maximal effects seen at a concentration of ImM ( Figure 4B).
  • the L-NMA-induced increase in p24 levels was abrogated by excess L-arginine but not D-arginine.
  • the actions of NO can be broadly classified as either cGMP dependent or independent. For example, much of the inhibitory effect of NO on platelets and smooth muscle is mediated by increases in cGMP levels due to activation of guanylate cyclase.
  • Figure 5 shows the effect of cGMP on HIV replication.
  • Peripheral blood mononuclear cells were infected witii HIV-1 and then grown in the presence or absence of SNAP.
  • NAP or the cGMP analog 8-bromo-cGMP.
  • p24 antigen levels were measured in the cell supernatants.
  • activation of guanylate cyclase may be one of the mechanisms by which NO inhibits HIV replication since ImM 8-bromo-cGMP (a cGMP analog) caused a three- fold inhibition of HIV replication (Figure 5); however, other mechanisms may also be involved in the NO- induced inhibition of HIV replication since NO-generating compounds can decrease HIV replication 7 fold without significantly inhibiting cellular proliferation (150 uM).
  • the data represent the mean of duplicate cultures.
  • the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.

Abstract

Méthode de traitement d'une infection par rétrovirus, dans une cellule, un tissu ou un animal infectés, par l'administration d'une quantité capable d'inhiber la réplication du rétrovirus de monoxyde d'azote ou d'un composé donnant, libérant ou transférant du monoxyde d'azote. L'invention concerne également une méthode permettant d'empêcher ou de supprimer la latence du rétrovirus dans une cellule, un tissu ou un animal par l'administration à ces derniers d'un inhibiteur de synthase de monoxyde d'azote en quantité suffisante pour rendre le rétrovirus capable de réplication. Le traitement de l'infection par un rétrovirus latent dans une cellule, un tissu ou un animal consiste à administrer i)) un inhibiteur de synthase de monoxyde d'azote ou un capteur de monoxyde d'azote en quantité suffisante pour rendre le rétrovirus capable de réplication et ii) une quantité inhibant la réplication d'un agent antiviral. L'invention concerne une composition constituée i) d'un inhibiteur de synthase de monoxyde d'azote ou capteur de monoxyde d'azote en quantité suffisante pour rendre le rétrovirus capable de réplication et ii) une quantité, permettant l'inhibition de la réplication, d'un agent antiviral, dans un excipient pharmaceutiquement acceptable.
PCT/US1996/004084 1995-04-04 1996-03-26 Inhibition de la replication des retrovirus WO1996031217A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55271/96A AU5527196A (en) 1995-04-04 1996-03-26 Inhibiting retroviral replication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41604695A 1995-04-04 1995-04-04
US08/416,046 1995-04-04

Publications (2)

Publication Number Publication Date
WO1996031217A1 true WO1996031217A1 (fr) 1996-10-10
WO1996031217A9 WO1996031217A9 (fr) 1996-11-28

Family

ID=23648310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004084 WO1996031217A1 (fr) 1995-04-04 1996-03-26 Inhibition de la replication des retrovirus

Country Status (2)

Country Link
AU (1) AU5527196A (fr)
WO (1) WO1996031217A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033823A1 (fr) * 1997-12-23 1999-07-08 Nycomed Imaging As Chelateurs liberant de l'oxyde nitrique et leur emploi a des fins therapeutiques
WO2000030659A1 (fr) * 1998-11-23 2000-06-02 Pulmonox Medical Corporation Procede et appareil permettant de traiter des infections respiratoires par inhalation d'oxyde nitrique
DE10303196A1 (de) * 2003-01-28 2004-08-12 Märtz, Hans Helmut Verwendung von Erzeugnissen, Stoffen oder Stoffgemischen, aus welchen im menschlichen oder tierischen Körper Stickoxid (Formel: NO) entsteht, zur Behandlung oder Prophylaxe von Infektionskrankheiten des menschlichen oder tierischen Körpers
US6793644B2 (en) 2000-12-26 2004-09-21 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
WO2004087212A2 (fr) * 2003-04-03 2004-10-14 Aga Ab Utilisation d'oxyde nitrique dans le traitement de l'inflammation
WO2007057763A2 (fr) * 2005-11-18 2007-05-24 Pulmonox Technologies Corporation Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin
US7335181B2 (en) 2000-12-26 2008-02-26 Pulmonox Technologies Corporation Nitric oxide decontamination of the upper respiratory tract
WO2008005313A3 (fr) * 2006-06-30 2008-02-28 Noxilizer Inc Système et dispositif de stérilisation
US7503322B2 (en) * 2003-09-12 2009-03-17 Harris Michael F Methods for the treatment of HIV and other viruses
US8425837B2 (en) 2009-02-23 2013-04-23 Noxilizer, Inc. Device and method for gas sterilization
US20140038963A1 (en) * 2011-04-04 2014-02-06 Sidney Hecht Multifunctional Radical Quenchers For The Treatment Of Mitochondrial Dysfunction
US8703066B2 (en) 2004-01-07 2014-04-22 Noxilizer, Inc. Sterilization system and method
US10364227B2 (en) 2015-02-17 2019-07-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10472340B2 (en) 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002964A (en) * 1988-06-15 1991-03-26 Brigham & Women's Hospital S-nitrosocaptopril compounds and the use thereof
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002964A (en) * 1988-06-15 1991-03-26 Brigham & Women's Hospital S-nitrosocaptopril compounds and the use thereof
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE, Vol. 261, issued 10 September 1993, KARUPIAH et al., "Inhibition of Viral Replication by Interferon-Delta Induced Nitric Oxide Synthase", pages 1445-48. *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391895B1 (en) 1997-12-23 2002-05-21 Amersham Health As Nitric oxide releasing chelating agents and their therapeutic use
WO1999033823A1 (fr) * 1997-12-23 1999-07-08 Nycomed Imaging As Chelateurs liberant de l'oxyde nitrique et leur emploi a des fins therapeutiques
WO2000030659A1 (fr) * 1998-11-23 2000-06-02 Pulmonox Medical Corporation Procede et appareil permettant de traiter des infections respiratoires par inhalation d'oxyde nitrique
US6793644B2 (en) 2000-12-26 2004-09-21 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7335181B2 (en) 2000-12-26 2008-02-26 Pulmonox Technologies Corporation Nitric oxide decontamination of the upper respiratory tract
DE10303196A1 (de) * 2003-01-28 2004-08-12 Märtz, Hans Helmut Verwendung von Erzeugnissen, Stoffen oder Stoffgemischen, aus welchen im menschlichen oder tierischen Körper Stickoxid (Formel: NO) entsteht, zur Behandlung oder Prophylaxe von Infektionskrankheiten des menschlichen oder tierischen Körpers
WO2004087212A2 (fr) * 2003-04-03 2004-10-14 Aga Ab Utilisation d'oxyde nitrique dans le traitement de l'inflammation
WO2004087212A3 (fr) * 2003-04-03 2004-12-16 Aga Ab Utilisation d'oxyde nitrique dans le traitement de l'inflammation
US7503322B2 (en) * 2003-09-12 2009-03-17 Harris Michael F Methods for the treatment of HIV and other viruses
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
US8808622B2 (en) 2004-01-07 2014-08-19 Noxilizer, Inc. Sterilization system and device
US9180217B2 (en) 2004-01-07 2015-11-10 Noxilizer, Inc. Sterilization system and device
US8703066B2 (en) 2004-01-07 2014-04-22 Noxilizer, Inc. Sterilization system and method
WO2007057763A2 (fr) * 2005-11-18 2007-05-24 Pulmonox Technologies Corporation Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin
WO2007057763A3 (fr) * 2005-11-18 2008-07-17 Pulmonox Technologies Corp Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin
WO2008005313A3 (fr) * 2006-06-30 2008-02-28 Noxilizer Inc Système et dispositif de stérilisation
US8425837B2 (en) 2009-02-23 2013-04-23 Noxilizer, Inc. Device and method for gas sterilization
US8721984B2 (en) 2009-02-23 2014-05-13 Noxilizer, Inc. Device and method for gas sterilization
US9102626B2 (en) * 2011-04-04 2015-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
US20140038963A1 (en) * 2011-04-04 2014-02-06 Sidney Hecht Multifunctional Radical Quenchers For The Treatment Of Mitochondrial Dysfunction
US9388163B2 (en) 2011-04-04 2016-07-12 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
US10364227B2 (en) 2015-02-17 2019-07-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10472340B2 (en) 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
US11034662B2 (en) 2015-02-17 2021-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses

Also Published As

Publication number Publication date
AU5527196A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
US5583101A (en) Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
WO1996031217A1 (fr) Inhibition de la replication des retrovirus
WO1996031217A9 (fr) Inhibition de la replication des retrovirus
ES2312012T3 (es) Nuevos compuestos de telurio y su uso como inmunomodulares.
Baba et al. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
Sappey et al. Iron Chelation Decreases NF-k B and HIV Type 1 Activation due to Oxidative Stress
EP0735890B1 (fr) Melanges de 2&#39;,3&#39;-didesoxy-inosine et d&#39;hydroxycarbamide utilises dans l&#39;inhibition de la propagation d&#39;un retrovirus
Malley et al. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2', 3'-dideoxyinosine in infected resting human lymphocytes.
WO1996002241A9 (fr) Utilisation d&#39;une espece d&#39;oxyde d&#39;azote et d&#39;adjuvants pour inhiber la contraction des muscles squelettiques
HUT67031A (en) Process for production of preparations for treatment of hiv infection
ES2389078T3 (es) Tratamiento de infecciones virales
Mannick et al. Nitric oxide modulates HIV-1 replication
Garg et al. Effect of nitric oxide on mitogenesis and proliferation of cerebellar glial cells
Eder et al. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents
US20100062081A1 (en) Use of tellurium containing compounds as nerve protecting agents
DK166715B1 (da) Farmaceutiske produkt og anvendelse af dette til fremstilling af et kombinationspraeparat til behandling af virusinfektioner
US5073571A (en) Method of inhibiting virus
WO1996002268A1 (fr) Inhibition d&#39;un virus par l&#39;oxyde nitrique
WO1996003139A1 (fr) Utilisation de l&#39;oxyde nitrique ou de ses produits d&#39;addition pour la conservation des plaquettes
US6686333B1 (en) Inhibition of HIV replication using soluble Tat peptide analogs
KR20050040907A (ko) 항종양 활성 증강용 화학요법제의 조합
AU2002360829B2 (en) Method for treating patients for radiation exposure
CN111315374A (zh) 合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物
HRP20221110T1 (hr) Parapoxvirus za kondicioniranje i liječenje infekcija uzrokovanih koronavirusom
CZ55995A3 (en) Inhibition of retroviral infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-28,DESCRIPTION,REPLACED BY NEW PAGES 1-29;PAGES 29-36,CLAIMS,REPLACED BY NEW PAGES 30-36;PAGES 1/5-5/5,DRAWINGS,REPLACED BY NEW PAGES 1/6-6/6;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA